Human umbilical cord blood‐derived mesenchymal stem cells improve functional recovery through thrombospondin1, pantraxin3, and vascular endothelial growth factor in the ischemic rat brain
Authors:
- 2 September 2015
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 93 (12) , 1814-1825
Abstract
Cell therapy is a potential therapeutic method for cerebral ischemia, which remains a serious problem. In the search for more effective therapeutic methods, many kinds of stem cells from various tissues have been developed and tested as candidate therapeutic agents. Among them, human umbilical cord blood (hUCB)‐derived mesenchymal stem cells (MSCs) are widely used for cell therapy because of their genetic flexibility. To confirm that they are effective and understand how they affect ischemic neural cells, hUCB‐MSCs were directly administered ipsilaterally into an ischemic zone induced by middle cerebral artery occlusion (MCAO). We found that the neurobehavioral performance of the hUCB‐MSC group was significantly improved compared with that of the vehicle‐injected control group. The infarct was also remarkably smaller in the hUCB‐MSC group. Additionally, hUCB‐MSC transplantation resulted in a greater number of newly generated cells and angiogenic and tissue repair factors and a lower number of inflammatory events in the penumbra zone. To determine why these events occurred, hUCB‐MSCs were assayed under hypoxic and normoxic conditions in vitro. The results showed that hUCB‐MSCs exhibit higher expression levels of thrombospondin1, pantraxin3, and vascular endothelial growth factor under hypoxic conditions than under normoxic conditions. These results were found to be correlated with our in vivo immunofluorescent staining results. On the basis of these findings, we suggest that hUCB‐MSCs may have a beneficial effect on cerebral ischemia, especially through angiogenesis, neurogenesis, and anti‐inflammatory effects, and thus could be used as a therapeutic agent to treat neurological disorders such as cerebral ischemia.Keywords
Funding Information
- Korea Institute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries, Republic of Korea (311011-05-3-SB020)
- Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI09C13540100, HI10C14110400, HI12C02050101.)
This publication has 49 references indexed in Scilit:
- Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesisCardiovascular Research, 2011
- Human Umbilical Mesenchymal Stem Cells Promote Recovery After Ischemic StrokeStroke, 2011
- Delayed Administration of Human Umbilical Tissue-Derived Cells Improved Neurological Functional Recovery in a Rodent Model of Focal IschemiaStroke, 2011
- Thrombospondin‐1 binds to ApoER2 and VLDL receptor and functions in postnatal neuronal migrationThe EMBO Journal, 2008
- Demyelinating diseases and potential repair strategiesInternational Journal of Developmental Neuroscience, 2007
- Neural stem cells and their use as therapeutic tool in neurological disordersBrain Research Reviews, 2005
- In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cellsBiochemical and Biophysical Research Communications, 2004
- Present situation and future aspects of spinal cord regenerationJournal of Orthopaedic Science, 2004
- Reduction of Ischemic Damage by Application of Vascular Endothelial Growth Factor in Rat Brain after Transient IschemiaJournal of Cerebral Blood Flow & Metabolism, 1998
- VEGF and fltStroke, 1996